Clinical trial shows immunotherapy drug pembrolizumab …
22 hours ago · The findings, published in The Lancet, establish pembrolizumab as a new option for patients with this disease. "Soft tissue sarcoma is a rare and complex disease with over 50 different subtypes ...
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative …
Jul 20, 2022 · Pembrolizumab monotherapy has shown durable antitumor activity in advanced triple-negative breast cancer, 6-9 particularly as first-line therapy, with improved clinical responses observed among...
Adjuvant Keytruda Improves Kidney Cancer Survival - NCI
May 21, 2024 · Pembrolizumab (Keytruda) treatment after surgery helped people with clear-cell renal cell carcinoma live longer in a large trial—a first for this cancer.
FDA approves pembrolizumab with chemotherapy for …
On September 17, 2024, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with pemetrexed and platinum chemotherapy as first-line treatment of unresectable advanced or ...
FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of ... - Merck
Jul 27, 2021 · FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Single Agent as Adjuvant Treatment After Surgery. Save. July 27, 2021 6:30 am ET.
FDA approves pembrolizumab for high-risk early-stage triple …
On July 26, 2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for high-risk, early-stage, triple-negative breast cancer (TNBC) in combination with chemotherapy...
Neoadjuvant Pembrolizumab Improves Event-Free Survival in …
Aug 10, 2021 · The latest analysis of the pivotal phase III KEYNOTE-522 trial demonstrated significant improvements in clinical outcomes with pembrolizumab plus chemotherapy vs chemotherapy alone as a neoadjuvant/adjuvant treatment of triple-negative breast cancer. 1 This is the first large, randomized, phase III trial to report a statistically significant ...
FDA approves pembrolizumab with chemotherapy for HER2 …
On November 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of...
Pembrolizumab for Advanced Triple-Negative Breast Cancer
Aug 9, 2022 · Adding the immunotherapy drug pembrolizumab (Keytruda) to chemotherapy can help some patients with advanced triple-negative breast cancer live longer than if they received chemotherapy alone, new results from a clinical trial show.
Pembrolizumab in the Treatment of Breast Cancer
Jul 20, 2022 · In this issue of the Journal, Cortes et al. 1 report that pembrolizumab — a breakthrough therapeutic treatment for patients with advanced triple-negative breast cancer — combined with...